FOLDNEUTRAL

EV/EBITDA

112.0x

Higher than 98% of Healthcare sector peers

Updated 94h ago

Sector Performance

98th percentile

FOLD

112.0x

Sector Median

12.8x

Sector Avg

15.6x

📊

Deep Analysis

Amicus Therapeutics's current enterprise-value-to-EBITDA (EV/EBITDA) ratio of 112.0x means investors are paying $112 for each dollar of the company's earnings before interest, taxes, depreciation, and amortization — a very high premium relative to profitability.

This ratio sits far above the healthcare sector median of 13.1x, placing the stock in the 98th percentile among its sector peers, indicating extreme valuation compared to similar companies. The year-over-year change is not available, but the quarter-over-quarter change shows the metric rose 29.3%, from 86.6x to 112.0x, signaling a rapid increase in valuation over the most recent period. The combination of an already elevated level and a sharp upward trend suggests heightened risk, as the stock's price has moved further from its underlying earnings base, making it vulnerable to corrections if growth expectations are not met. This extreme valuation multiple does not support the overall NEUTRAL verdict, as it points to stretched pricing that typically warrants caution rather than a balanced view.

Frequently Asked Questions

What does the EV/EBITDA tell investors about FOLD?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does FOLD's EV/EBITDA compare to its sector?

FOLD's EV/EBITDA of 112.0x compares to a Healthcare sector median of 12.8x, placing it in the 98th percentile.

Who are FOLD's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: GSK (10.2x), CPRX (10.1x), ZBH (9.7x), BAX (9.4x), BIIB (8.8x).

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.